Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Physician Practice Oversight topic
No spam. Unsubscribe anytime.
State pain committee urges substance‑abuse CME and tighter monitoring after review of Dr. Jefferson's prescribing
Summary
The Arkansas State Medical Board Pain Committee reviewed Dr. Thomas Jefferson’s records and recommended substance‑abuse continuing medical education, more frequent confirmatory drug testing (mass spec), improved documentation and a six‑month follow‑up on his submitted corrective action plan.
The Arkansas State Medical Board Pain Committee recommended that Dr. Thomas Jefferson complete a substance‑abuse continuing medical education course and tighten monitoring of patients after reviewing his prescribing records on July 17, 2025.
Dr. Ramon, who led the committee, said members were concerned by “inconsistent drug screens and a lot of polypharmacy,” noting combinations of benzodiazepines, stimulants and opioids among Jefferson’s patients that raise diversion risks. The committee said some point‑of‑care screens produced inconsistent results and recommended more routine confirmatory GC‑MS/mass‑spec testing for high‑risk patients.
Jefferson, in the virtual meeting, described his clinical background and patient mix. He said he is boarded in pediatrics, has worked in HIV and transgender care, runs Health for Life Clinic and provides medication‑assisted treatment. He told the committee that nursing staff document point‑of‑care screens and that positive screens are sent to LabCorp for confirmation, which can take more than a week. He also said his clinic is federally funded and that administrative steps can complicate terminating patients.
Committee members pressed Jefferson on specific cases: several patients had negative point‑of‑care urine tests for medications that remained on their prescriptions, and one 31‑year‑old patient with a history of cocaine use was receiving stimulants. “If the patient’s drug screen is negative and they are not in active withdrawal, they’re probably OK without it,” said Doctor Tilley, who praised Jefferson’s corrective action plan but urged stricter follow‑up.
Members recommended several corrective steps: reduce or eliminate unnecessary combinations of stimulants, benzodiazepines and opioids; increase use of confirmatory mass‑spec testing (especially for patients with inconsistent point‑of‑care results); improve narrative documentation in the electronic health record to explain prescribing decisions; and refer patients with complex stimulant histories to psychiatry when appropriate.
Doctor Tilley moved that the committee recommend Jefferson complete a board‑approved substance‑abuse CME course and reconvene in six months to review cleaned records and his corrective action plan; Dr. Ramon seconded the motion. The committee approved the recommendation by voice consensus.
The committee also noted it will follow up on related Prescription Drug Monitoring Program (PDMP) reports at a later meeting and asked the Attorney General’s office representative to research how federal funding and administrative procedures affect a clinic’s ability to terminate patient prescriptions; the AG representative said they would need to look into the issue.
The committee closed by saying it intends to review Jefferson’s documentation and drug‑screen follow‑up in six months to determine whether the corrective actions have been implemented.
